The World Hypertension Market 2007-2023

Table of Contents

1. Executive Summary - Hypertension is a Serious Cause of Mortality Worldwide

2. Introduction to Hypertension

• 2.1 An Overview of Hypertension
• 2.2 Symptoms of Hypertension and Diagnosis of the Condition
• 2.3 Causes of Hypertension
• 2.4 Primary Hypertension
• 2.5 Secondary Hypertension
• 2.6 Pulmonary Hypertension
• 2.7 Epidemiology of Hypertension
• 2.8 Links with Other Disorders
• 2.9 The Treatment of Hypertension
  • 2.9.1 Countering Hypertension Through Changes in Diet and Lifestyle - A First Line of Attack
  • 2.9.2 Treatment Targets and the Selection of Drugs
  • 2.9.3 Beta Blockers
  • 2.9.4 Angiotensin Converting Enzyme (ACE) Inhibitors
  • 2.9.5 Calcium-Channel Blockers
  • 2.9.6 Angiotensin II Blockers
  • 2.9.7 Alpha Blockers
  • 2.9.8 Diuretics
  • 2.9.9 Tekturna/Rasilez (aliskiren) - a First-In-Class Renin Inhibitor
  • 2.9.10 Other Drugs
• 2.10 The Treatment of Pulmonary Hypertension
• 2.11 The Prospects for Patients

3 The World Hypertension Market, 2007-2023

• 3.1 Growing Demand and Shifting Internal Dynamics in the World Anti-hypertensive Market, 2007-2023
• 3.2 Novartis to Become the Leading Company in the Hypertension Market by the End of the Decade
• 3.3 Angiotensin II Blockers to Continue Their Domination of the Anti-hypertensive Market, 2006 Onwards
• 3.4 Other Classes of Anti-hypertensive Drug Will Display High Revenues during 2006-2012
• 3.5 Calcium Channel Blockers - Declining Revenues due to Heightened Competition
• 3.6 Angiotensin Converting Enzyme (ACE) Inhibitors - Will This Class Be Superseded by the Angiotensin II Blockers?
• 3.7 Beta-Blockers - Carving a Secure Niche in a Highly Competitive Market?
• 3.8 Alpha Blockers Will Maintain a Respected Position in the Hypertension Market
• 3.9 Competition in the Anti-hypertensive Market to Become Increasingly Intense
• 3.10 Monotherapy or Combination Therapy?
• 3.11 Diuretic Agents Retain Importance

4. The World Market for Angiotensin II Blockers, 2007-2023

• 4.1 Angiotensin II Blockers - Strong Growth Leads to Continuing Predominance in the Market
  • 4.1.1 The Angiotensin II Blockers Will Benefit From More Secure Patent Protection Than The Other Classes of Antihypertensives
  • 4.1.2 Other Advantages of Angiotensin II Blockers That Confer Important Benefits in the Market
• 4.2 Diovan to Take Market Leadership from Norvasc by 2007
  • 4.2.1 Diovan/Co-Diovan Benefits From High Prescription Rates in the US Market
  • 4.2.2 Paediatric Exclusivity Granted by FDA in 2007
  • 4.2.3 Approval for Reduction of Cardiovascular Death
  • 4.2.4 Diovan Benefits from Further Clinical Studies
  • 4.2.5 Recent Support from The European Society of Cardiology
  • 4.2.6 The AVVANCE Trial Provided Further Support for Diovan
  • 4.2.7 The NAVIGATOR Trial for Improved Glucose Tolerance
• 4.3 Cozaar/Hyzaar - High Revenues Followed by Decline
  • 4.3.1 Development for Diabetic Nephropathy - The RENAAL study
  • 4.3.2 FDA Approval for LVH
  • 4.3.3 Diabetic Nephropathy Approval in Japan During 2006
  • 4.3.4 Further Developments for Cozaar/Hyzaar
• 4.4 Avapro/Aprovel/Avalide to Maintain Steady Growth
  • 4.4.1 Avaprovel/Avapro Benefits from Continuing Development
  • 4.4.2 BMS Places High Emphasis on Irbesartan
  • 4.4.3 Sublicensing of Irbesartan for Japanese Market
• 4.5 Blopress - Another Strong Performer
  • 4.5.1 Additional FDA Approval for Blopress
• 4.6 Micardis Will Become a Leading Blockbuster by the End of the Decade
  • 4.6.1 Micardis Shows Potential Metabolic Benefits
  • 4.6.2 Micardis Benefits from Further Clinical Studies
  • 4.6.3 Further Clinical Studies May Confer a Market Advantage to Micardis
• 4.7 Benicar/Olmetec' s Revenue Growth Set to Continue Steadily
  • 4.7.1 Further Licensing Agreements for Benicar
  • 4.7.2 Promising Results from Further Clinical Study
  • 4.7.3 Sankyo Used Licensing Deals for International Marketing
  • 4.7.4 The ORIENT Study and Other Developments
• 4.8 Exforge Will Achieve Blockbuster Revenues by The End of the Decade
• 4.9 Other Agents Will Have an Increasing Presence in the Angiotensin II Blockers Market

5 The World Market for Calcium Channel Blockers, 2006-2023

• 5.1 Increased Competition Will Lower Revenues Among the Calcium Channel Blockers
• 5.2 Norvasc - 2006 Hypertension Market Leader Set to Lose Dominance to Leading Angiotensin II Blockers
  • 5.2.1 Norvasc is Going To Suffer from Prescribing Shift to Angiotensin II Antagonists
  • 5.2.2 Norvasc Has Faced Serious Patent Challenges
  • 5.2.3 Norvasc Benefits from Further Clinical Testing
  • 5.2.4 Active Ingredient in Norvasc Combined with that of Lipitor to Form Dual Action Cardiovascular Drug
  • 5.2.5 New Combination Product Exforge Will Draw Sales from Both Norvasc and Diovan
• 5.3 Lotrel Reaches Blockbuster Revenue Levels then Declines
  • 5.3.1 Lotrel is a Prominent Combination Product
  • 5.3.2 The ACCOMPLISH Study for High Risk Hypertension
• 5.4 Adelat Faces a Gradual Decline
  • 5.4.1 Adelat is a Fine Example of Lifecycle Prolongation
• 5.5 Amlodin Follows the General Trend for Calcium Blockers
• 5.6 Other Agents Will Exert An Increasing Presence in the Calcium Blocker Market

6. The World Market for Beta-Blockers, 2006-2023

• 6.1 Beta Blockers Will Retain Their Niche Despite a Marked Decline in Sales
  • 6.1.1 Uses and Limitations of Beta Blockers That Affect Their Position In The Market
• 6.2 Toprol-XL/Seloken Will Remain the Most Important Beta Blocker from 2007 Onwards
  • 6.2.1 Approval for Cardiac Failure
  • 6.2.2 Toprol-XL Faces Patent Challenges
• 6.3 Coreg Will Be The Second Largest Beta blocker from 2007 Onwards
  • 6.3.1 Coreg Faces Increasing Generic Competition
  • 6.3.2 Coreg May Benefit From Further Clinical Studies
  • 6.3.3 Licensing of Carvedilol
• 6.4 Concor/Bisoprolol
  • 6.4.1 Phase III Trials in Japan for Chronic Heart Failure
• 6.5 Other Agents Will Have an Increasing Presence in the Beta Blocker Market

7 The World Market for ACE Inhibitors, 2006-2023

• 7.1 How Well Will The ACE Inhibitors Resist Competition From The Angiotensin II Blockers?
  • 7.1.1 ACE Inhibitors Will Retain Prominence in The Market
• 7.2 Delix/Tritace Will Retain Predominance in this Class
  • 7.2.1 Licensing Agreements for International Distribution
  • 7.2.2 Further Clinical Studies and Life Cycle Management to Confer Benefits to Delix/Tritace
• 7.3 Altace Will Maintain Second Place in the ACE inhibitor Market
• 7.4 Vasotec/Vaseretic - This Older Drug Will Face Decline
  • 7.4.1 Enalapril is a Versatile ACE Inhibitor
  • 7.4.2 Additional Clinical Studies and Product Development to Benefit Vasotec
• 7.5 Other Agents Will Have an Increasing Presence in the ACE inhibitors Market

8. The World Market for Alpha Blockers, 2006-2023

• 8.1 Alpha blockers Will Lose Prominence in the Hypertension Market
  • 8.1.1 Alpha Blockers Are Also Used to Treat BPH
  • 8.1.2 Limitations On The Use of Alpha Blockers Influence Their Performance in The Market
• 8.2 Cardura Will Dominate the Alpha Blocker Class
• 8.3 Other Agents Will Have an Increasing Presence in the Alpha blocker Market

9 The World Market for Other Hypertensive Agents, 2006-2023

• 9.1 Will New Antihypertensive Classes Such As the Renin Inhibitors Challenge the Established Agents?
• 9.2 Tracleer - a Blockbuster of the Future
  • 9.2.1 Tracleer is the First of the Endothelin Receptor Antagonists and a Major Advance in the Treatment of Pulmonary Arterial Hypertension
  • 9.2.2 European Approval for Digital Ulcers In Patients With Systemic Sclerosis And Ongoing Digital Ulcer Disease
  • 9.2.3 Trials for Congestive Heart Failure
• 9.3 Tekturna/Rasilez - The Trailblazer of the New Renin Inhibitor Class
  • 9.3.1 Novartis Will Gain a Significant First-Mover Advantage With Aliskiren
  • 9.3.2 Approval and Launch of Aliskiren in the US
  • 9.3.3 EU Approval for Aliskiren in June 2007
• 9.4 Other Agents Will Have an Increasing Presence in This Group

10. An Analysis of Factors That Influence the Hypertension Market

• 10.1 SWOT Analysis of the Hypertension Market
• 10.2 An Expanding Patient Population Constitutes the Principal Driver in the Hypertension Market
• 10.3 The Hypertension Market Has Opportunities for Continuing Growth
• 10.4 Changes in Blood Pressure Treatment Guidelines - Can Both Patients and Drug Companies Benefit?
• 10.5 Advances in Technology Are Likely to Bring Benefits to the Market
• 10.6 The Principal Restraints in the Hypertension Market
• 10.7 To What Extent is the Hypertension Market Threatened by Generic Substitutes?
• 10.8 What Unmet Market Needs Exist in the Hypertension Market? - Experts Provide Their Views
  • 10.8.1 Resistant Hypertension Constitutes a Major Limitation of Present Treatments
  • 10.8.2 Important Patient Sub-Populations: Potential For Companies To Increase Market Leverage Through Product Differentiation
• 10.9 Comparative Studies - A Two Edged Sword

11. A Geographical Breakdown of the World Hypertension Market

• 11.1 The US Will Lead a High Revenue Global Market in 2010
• 11.2 The Prevalence of Hypertension Worldwide - Many Hypertensive People Currently Untreated or Under-treated
• 11.3 There is An Urgent Requirement To Expand the Treatment of Hypertension on a Global Scale

12. Pipeline Developments in Hypertension

• 12.1 Submitted and Approved Agents for Hypertension
  • 12.1.1 Tekturna HCT
  • 12.1.2 Cleviprex
  • 12.1.3 CS 8663
• 12.2 Phase III Developments for Hypertension
  • 12.2.1 Coreg CR Combination
  • 12.2.2 CS 866AZ
  • 12.2.3 Actelion 1
  • 12.2.4 Darusentan
• 12.3 Phase II Developments for Hypertension
  • 12.3.1 Ilepatril
  • 12.3.2 TAK 491
  • 12.3.3 PST 2238
  • 12.3.4 PF 489791
  • 12.3.5 Fimasartan
  • 12.3.6 SPP 635
  • 12.3.7 Daglutril
  • 12.3.8 NCX 4016
  • 12.3.9 SLx 2101
  • 12.3.10 Protherics' Immunotherapeutic Vaccine
  • 12.3.11 TBC 3711
  • 12.3.12 SB 221
  • 12.3.13 CYT006-AngQb
  • 12.3.14 MC-4232
  • 12.3.15 MK 0736
  • 12.3.16 MC-4262 from Medicure
• 12.4 Early Stage Developments in Hypertension
  • 12.4.1 MC 4262
  • 12.4.2 Actelion' s Renin Inhibitor Development with Merck & Co
  • 12.4.3 SPP 1148
  • 12.4.4 MC-1
• 12.5 The Renin Inhibitors May Be One of the Few Other Drugs To Challenge The Angiotensin II Inhibitors During The Forecast Period

13 Conclusions: Hypertension Constitutes a Large Drugs Market with Scope for Expansion Worldwide List of Figures

• 13.1 Hypertension is a Serious, Growing Problem Worldwide
• 13.2 Hypertension Constitutes a High Revenue Market with Continuing Growth Potential
• 13.3 Hypertension Drugs will Achieve High Revenues in all the Major Geographical Markets from 2005-2010
• 13.4 The Pipeline for Hypertension Drugs is Strong
• 13.5 Continuing Public and Private Sector Investment is Required

List of Tables

• Table 2.1, Categories for Blood Pressure in Adults
• Table 2.2, Leading Beta-Blockers to Treat Hypertension
• Table 2.3, Leading ACE Inhibitors to Treat Hypertension
• Table 2.4, Leading Calcium Channel Blockers to Treat Hypertension
• Table 2.5, Leading Angiotensin II Blockers to Treat Hypertension
• Table 2.6, Leading Alpha Blockers to Treat Hypertension
• Table 3.1, Blockbuster Drugs in the World Hypertension Market, 2006
• Table 3.2, World Revenues ($m) for the Leading Hypertension Drugs, by Class, 2006-2012
• Table 3.3, World Revenues ($m) for the Leading Hypertension Drugs, by Class, 2013-2023
• Table 3.4, World Market Revenue ($m), 6-Year CAGR (%) and Market Share (%) for Hypertension Drugs by Class, 2006 & 2012 Table 3.5, World Market Revenue ($m), 2012, and CAGR (%) for Hypertension Drugs by Class, 2012-2023
• Table 3.6, World Market Revenue ($m) and Change (%), 2006 and 2012
• Table 4.1, World Revenues ($m) for Angiotensin II Blockers, 2006-2012
• Table 4.2, World Revenues ($m) for Angiotensin II Blockers, 2013-2023
• Table 4.3, Patent Expiry for Leading Angiotensin II Blockers, 2007
• Table 4.4, World Market Revenue ($m) and Market Share (%) and 6-Year CAGR (%) for Angiotensin II Blockers, 2006 & 2012 Table 4.5, World Market Revenue ($m), 2012, and CAGR (%) for Angiotensin II Blockers, 2012-2023
• Table 5.1, World Revenues ($m) for Calcium Channel Blockers, 2006-2012
• Table 5.2, World Revenues ($m) for the Calcium Channel Blockers, 2013-2023
• Table 5.3, Patent Expiry for Calcium Channel Blockers to Treat Hypertension
• Table 5.4, World Market Revenue ($m) and Market Share (%) and 6-Year CAGR (%) for Calcium Channel Blockers, 2006 & 2012 Table 5.5, World Market Revenue ($m), 2012, and CAGR (%) for Calcium Channel Blockers, 2012-2023
• Table 6.1, World Revenues ($m) for Beta Blockers, 2006-2012
• Table 6.2, World Revenues ($m) for the Beta Blockers, 2013-2023
• Table 6.3, Patent Expiry for Beta-Blockers to Treat Hypertension
• Table 6.4, World Market Revenue ($m) and Market Share (%) and 6-Year CAGR (%) for Beta Blockers, 2006 & 2012
• Table 6.5, World Market Revenue ($m), 2012, and CAGR (%) for Beta Blockers, 2012-2023
• Table 7.1, World Revenues ($m) for ACE Inhibitors, 2006-2012
• Table 7.2, World Revenues ($m) for ACE Inhibitors, 2013-2023
• Table 7.3, Patent Expiry for ACE Inhibitors to Treat Hypertension
• Table 7.4, World Market Revenue ($m) and Market Share (%) and 6-Year CAGR (%) for ACE Inhibitors, 2006 & 2012
• Table 7.5, World Market Revenue ($m), 2012, and CAGR (%) for ACE Inhibitors, 2012-2023
• Table 8.1, World Revenues ($m) for Alpha Blockers, 2006-2012 Table 8.2, World Revenues ($m) for Alpha Blockers, 2013-2023 Table 8.3, Patent Expiry for Alpha Blockers to Treat Hypertension
• Table 8.4, World Market Revenue ($m) and Market Share (%) and 6-Year CAGR (%) for Alpha Blockers, 2006 & 2012
• Table 8.5, World Market Revenue ($m), 2012, and CAGR (%) for Alpha Blockers, 2012-2023
• Table 9.1, World Revenues ($m) for Other Agents, 2006-2012
• Table 9.2, World Revenues ($m) for Other Agents, 2013-2023
• Table 9.3, World Market Revenue ($m) and Market Share (%) and 6-Year CAGR (%) for Other Agents, 2006 & 2012
• Table 9.4, World Market Revenue ($m), 2012, and CAGR (%) for Other Agents, 2012-2023
• Table 10.1, Leading Anti-hypertensive Drugs That Face The Greatest Threat From Generic Competition, 2005
• Table 11.1, Estimated Hypertensive Patient Populations by Country, 2004
• Table 11.2, Estimated Total Sales ($m) For Hypertension Drugs by Leading National Market, 2006 and 2012
• Table 13.1, World Revenues ($m) for the Leading Hypertension Drugs, by Class, 2006-2012
• Table 13.2, World Revenues ($m) for the Leading Hypertension Drugs, by Class, 2013-2023
• Table 13.3, Estimated Total Sales ($m) For Hypertension Drugs by Leading National Market, 2006 and 2012

List of Figures

• Figure 3.1, World Revenues ($m) for the Leading Hypertension Drugs, by Class, 2006-2023
• Figure 3.2, World Revenues ($m) for the Leading Hypertension Drugs, by Class, 2006-2023
• Figure 3.3, World Market Share (%) for Hypertension by Class, 2006
• Figure 3.4, World Market Share (%) for Hypertension by Class, 2012
• Figure 3.5, Changes ($m) in World Revenues for the Classes of Hypertension Drugs, 2006-2012
• Figure 3.6, Changes (%) in World Revenues for the Classes of Hypertension Drugs, 2006-2012
• Figure 4.1, Total World Revenues ($m) for Angiotensin II Blockers, 2006-2023
• Figure 4.2, World Revenues ($m) for the Angiotensin II Blockers by Leading Product, 2006-2023
• Figure 4.3, World Market Share (%) for Angiotensin II Blockers, 2006
• Figure 4.4, World Market Share (%) for the Angiotensin II Blockers, 2012
• Figure 4.5, World Diovan Revenues ($m), 2006-2023
• Figure 4.6, World Cozaar/Hyzaar Revenues ($m), 2006-2023
• Figure 4.7, World Avapro/Aprovel and Avalide Revenues ($m), 2006-2023
• Figure 4.8, World Blopress Revenues ($m), 2006-2023
• Figure 4.9, World Micardis Revenues ($m), 2006-2023
• Figure 4.10, World Benicar/Olmetec Revenues ($m), 2006-2023
• Figure 4.11, World Exforge Revenues ($m), 2006-2023
• Figure 4.12, World Revenues ($m) for Other Angiotensin II Blockers, 2006-2023
• Figure 5.1, Total World Revenues ($m) for Calcium Blockers, 2006-2023
• Figure 5.2, World Revenues ($m) for the Calcium Blockers by Leading Product, 2006-2023
• Figure 5.3, World Market Share (%) for Calcium Blockers, 2006
• Figure 5.4, World Market Share (%) for the Calcium Blockers, 2012
• Figure 5.5, World Norvasc Revenues ($m), 2006-2023
• Figure 5.6, World Lotrel Revenues ($m), 2006-2023
• Figure 5.7, World Adalat Revenues ($m), 2006-2023
• Figure 5.8, World Amlodin Revenues ($m), 2006-2023
• Figure 5.9, World Revenues for Other Calcium Blockers ($m), 2006-2023
• Figure 6.1, Total World Revenues ($m) for Beta Blockers, 2006-2023
• Figure 6.2, World Revenues ($m) for the Beta Blockers by Leading Product, 2006-2023
• Figure 6.3, World Market Share (%) for Beta Blockers, 2006
• Figure 6.4, World Market Share (%) for the Beta Blockers, 2012
• Figure 6.5, World Toprol-XL/Seloken Revenues ($m), 2006-2023
• Figure 6.6, World Coreg Revenues ($m), 2006-2023
• Figure 6.7, World Concor/Bisoprolol Revenues ($m), 2006-2023
• Figure 6.8, World Revenues ($m) for Other Beta Blockers, 2006-2023
• Figure 7.1, Total World Revenues ($m) for ACE Inhibitors, 2006-2023
• Figure 7.2, World Revenues ($m) for the ACE Inhibitors by Leading Product, 2006-2023
• Figure 7.3, World Market Share (%) for ACE Inhibitors, 2006
• Figure 7.4, World Market Share (%) for the ACE Inhibitors, 2012
• Figure 7.5, World Delix/Tritace Revenues ($m), 2006-2023
• Figure 7.6, World Altace Revenues ($m), 2006-2023
• Figure 7.7, World Vasotec/Vaseretic Revenues ($m), 2006-2023
• Figure 7.8, World Revenues ($m) for Other ACE Inhibitors, 2006-2023
• Figure 8.1, Total World Revenues ($m) for Alpha Blockers, 2006-2023
• Figure 8.2, World Revenues ($m) for the Alpha Blockers by Leading Product, 2006-2023
• Figure 8.3, World Market Share (%) for Alpha Blockers, 2006
• Figure 8.4, World Market Share (%) for the Alpha Blockers, 2012
• Figure 8.5, World Cardura Revenues ($m), 2006-2023
• Figure 8.6, World Revenues ($m) for Other Alpha Blockers, 2006-2023
• Figure 9.1, Total World Revenues ($m) for Other Anti-Hypertensives, 2006-2023
• Figure 9.2, World Revenues ($m) for Other Anti-Hypertensives by Leading Product, 2006-2023
• Figure 9.3, World Market Share (%) for Other Anti-Hypertensives, 2006
• Figure 9.4, World Market Share (%) for Other Anti-Hypertensives, 2012
• Figure 9.5, World Tracleer Revenues ($m), 2006-2023
• Figure 9.6, World Tekturna/Rasilez Revenues ($m), 2006-2023
• Figure 9.7, World Revenues ($m) for Other Agents in This Group, 2006-2023
• Figure 10.1, A SWOT Chart for the Hypertension Market, 2005-2010
• Figure 11.1, Estimated Hypertensive Populations by Country, 2004
• Figure 11.2, Revenues ($m) for Hypertension Drugs by Country, 2006
• Figure 11.3, Revenues ($m) for Hypertension Drugs by Country, 2012

Companies Mentioned in This Report

• A Menarini AG
• Abbott
• Actelion
• Altana
• Andrx Pharmaceuticals
• Apotex
• Astellas Phama
• AstraZeneca
• Athena
• Biovail Corporation
• BLI Pharmaceutical Development Ltd
• BNC-Pharmapass LLC
• Boehringer Ingelheim
• Boryung Pharmaceutical Company
• Bristol-Myers Squibb
• CoTherix
• Cytos
• Daiichi Sankyo
• Discovery
• Dr Reddy' s Laboratories
• Ecosol AG
• Encysive Pharmaceuticals
• Eon Labs
• Forest Laboratories
• G. Streuli & Co AG
• Gilead
• GlaxoSmithKline
• Goldshield
• Helvepharm AG
• Ivax Pharmaceuticals
• Janssen Pharmaceutica N.V
• King
• Kowa
• KV Pharmaceutical Company
• Kyowa Hakko Kogyo
• Lederle
• Lexicon Genetics Incorporated
• LifeCycle Pharma
• Lupin
• Medicure
• Medika AG
• Menarini
• Mepha Pharma AG
• Merck & Co
• Merck KGaA
• Mutual Pharmaceutical
• Mylan
• Mylan Bertek Pharmaceuticals
• Mylan Laboratories
• Myogen
• Neopharm
• NicOx
• Novartis
• Par Pharmaceuticals
• Penwest Pharmaceuticals Co
• Pfizer
• Protherics
• Ranbaxy
• Recordati
• Robapharm AG
• Roche
• Sandoz
• Sankyo Pharma
• Sanofi-Aventis
• Santen
• Schering AG
• Schwarz Pharmaceutical
• Sepracor
• Shionogi
• Shire Pharmaceuticals
• Solvay
• Speedel
• Spirig Pharma AG
• SunTen Phytotech
• Surface Logix
• Takeda Pharmaceutical
• Tanabe Seiyaku
• Teva
• The Medicines Company
• Watson
• Wyeth Pharmaceuticals